



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q4
2025

ANDREAS NIEDERMAIER, CEO
ANDREAS LÖSLER, CFO

February 27, 2026

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q4 2025


- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

ALZCHEM AT A GLANCE

Another successful year added




SALES GROWTH



(1) 2020 COVID-19 pandemic start
(2) 2022 Ukraine war

EBITDA GROWTH



(1) 2020 COVID-19 pandemic start
(2) 2022 Ukraine war

OUR MARKETS



HEALTH & NUTRITION



ANIMAL NUTRITION



FINE CHEMISTRY



SAFETY & DEFENSE



AGRICULTURE



RENEWABLE ENERGIES



METALLURGY



AUTOMOTIVE



AGRI SOLUTIONS



CUSTOM SYNTHESIS



PHARMA



Based on our unique "Verbund production"

HIGHLIGHTS

Alzchem has delivered again



Growth expectations fulfilled:
+ 2% revenue growth
+ 11% EBITDA growth



Free float increased to 74% leading to higher stock trading volumes



EBITDA margin exceeds 20% for the first time



Further growth expected in 2026, despite huge investment programs



Group earnings increased to €64m – 17% growth
Dividend proposal of €2.10 – 17% increase



€120m creatine expansion program initiated with major growth potential for 2027



Update on Nitroguanidine expansion

- ✓ Construction activities for Nitroguanidine expansion in Germany are on track
- ✓ Frequent and close discussions with existing and new customers about their growth projects
- ✓ Site selection for US expansion is nearing the finish line

CREATINE CAPACITY EXPANSION

Additional capacity in the sports, food and health sectors



Investment decision and announcement

project planning

construction

H2 2027

commissioning

- **Total investment:** ~ EUR 120 million
- **Scope:** Highly automated production plant for creatine and its precursors and upstream infrastructure (e.g. raw materials, waste reduction, laboratories)
- **Impact:** Additional annual sales potential in the early triple-digit million range with correspondingly positive earnings contribution

- Strengthening Alzchem's position as the only western producer of high-purity creatine
- Increasing supply capacity for Creapure® (sports nutrition) and Creavitalis® (health & nutrition)
- Enabling expansion into new application fields



Creapure®

Creavitalis®

AGENDA – ANALYST PRESENTATION Q4 2025

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)




Sales and EBITDA reductions on expected level

SALES




SALES



EBITDA



EBITDA




SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	- 21.7%	- 11.0%
Price	+ 1.8%	+ 0.1%
Currency	- 0.2%	+ 0.0%

COMMENTS

- Sales decline on expected level; mainly resulting from reduced quantities
- Most impact from ongoing weak economics within metallurgical sector in the European steel market
- Electricity costs slightly higher compared to last year with adverse cost effect on EBITDA
- Inventory level on expected high level in preparation for longer maintenance shut down of carbide furnace in 2026



CREAMINO Dormex® Bioselect® **DYHARD®**  **Creapure®**

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality specialty chemical ingredients with strong growth perspectives.

SPECIALTY CHEMICALS SEGMENT (in M€)


Segments growth trend continued




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	+ 7.5%	+ 7.4%
Price	+ 4.2%	+ 2.6%
Currency	- 2.4%	- 1.2%

COMMENTS

- The substantial growth in sales and EBITDA was mainly attributed to:
 - Human Nutrition** – Growing global demand of Creapure® and Creavitalis®
 - Custom Manufacturing** – Upward trend within the German and European chemical industries
- New creatine added capacity and sold volumes added capacity in Q4 already



OTHER & HOLDING

The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)

Regulated grid fees impact sales and result




SALES



EBITDA



SALES



EBITDA



COMMENTS

- Slight reduction in sales development compared to the previous year
- Sales & EBITDA development mainly resulting from reduced grid fee charges to chemical park customers
- Special impact on segments result due to regulatory provision for network prices
 - mostly eliminated on group level and shown as consolidation impact in groups segment reporting

FINANCIAL OVERVIEW

All KPI above prior year – net income follows EBITDA growth



Alzchem Group	Q4 2024	Q4 2025	qoq %	2024 1 - 12	2025 1 - 12	yoy %
SALES (in M€)	139.0	137.3	-1.3%	554.2	562.1	+1.4%
EBITDA (in M€)	28.5	30.3	+6.5%	105.3	116.5	+10.6%
EBITDA margin (in %)	20.5%	22.1%	+1.6 pp	19.0%	20.7%	+1.7 pp
Earnings per Share (in €)	1.49	1.66	+11.4%	5.31	6.28	+18.3%

- Specialty Chemicals segment more than offsets declines in other segments – increase is driven by positive price and volume effects
- Material sales increases could be achieved in the NAFTA and European market
- Personnel expenses impacted by collective wage increases and slightly higher FTE following the growth programs
- Increased sales portion of Specialty Chemicals support increase in EBITDA as well as EBITDA-margin
- Improved financial result supports positive development in net result and EPS

SALES ANALYSIS	DELTA Q4	DELTA 01 - 12
Volume	-3.0%	+0.3%
Price	+3.4%	+1.8%
Currency	-1.6%	-0.7%

BALANCE SHEET & CASHFLOW

Strong Equity / Net Cash Position / Positive Free Cashflow



Balance sheet KPIs (T€)	31.12.2024	31.12.2025	Deviation	
Balance sheet total	483,826	617,679	133,852	27.7%
Inventories	101,166	116,004	14,838	14.7%
Equity	207,471	258,231	50,760	24.5%
Equity ratio	42.9%	41.8%	-1.1 pp	
Liabilities to Banks	48,671	41,118	- 7,553	-15.5%
Cash and cash equivalents	61,544	71,720	10,176	16.5%
Net financial debt (-) / asset (+)	12,873	30,602	17,729	137.7%

Cashflow KPIs (T€)	1 - 12 2024	1 - 12 2025	Deviation	
Operating Cashflow	105,147	137,013	31,866	30.3%
Investing Cashflow	- 30,994	- 96,902	- 65,908	212.6%
Free Cashflow	74,153	40,111	- 34,041	-45.9%
Financial Cashflow	- 24,655	- 29,360	- 4,705	19.1%
Net increase in cash	49,497	10,751	- 38,746	-78.3%

COMMENTS

- Increase in balance sheet total resulting from increased CAPEX and customer grants
- Planned inventory increase in preparation for carbide furnace maintenance
- Net financial assets at balance sheet date
- Customer grants for Nitroguanidine expansion led to stable operating cashflow despite increased working capital
- Investing cashflow highly above prior year as Nitroguanidine expansion is on schedule
- Higher dividend payments and share buyback program influence financing cash flow
- Pension obligation on reduced level as interest rates increased to 4.1%

KPI impact of nitroguanidine expansion 1-12/2025 in M€




OUTLOOK 2026 (in M€)


Ongoing growth in sales and EBITDA despite high investments



SALES



EBITDA



COMMENTS

Assumptions

- No global recession; stable world economy with raw material and logistics costs remain at current levels
- Electricity prices remain high at 2025 levels
- No major impacts from the US tariffs policy and US-Dollar exchange rate stays at the same level as end of 2025
- First quantities from new NQ-plant will be delivered

Sales Growth

- Organic growth, no acquisitions
- Specialty Chemicals: Growth mainly through increased volumes of Creapure® and Nitroguanidin
- Basics & Intermediates: Sales remain on previous year level. Potential negative impact by quantity losses due to abandonment of low-price business

EBITDA Growth

- Further increase in higher-margin specialty chemical sales will increase EBITDA as well
- Furnace maintenance shut down will impact profit & loss

Other KPI

- Inventory with strong decrease
- Equity ratio with slight decrease

FINANCIAL CALENDAR

Upcoming dates*



FEB 27	2026	Annual Report 2025
MAR 5	2026	Berenberg EU Opportunities Conference London
MAR 26	2026	Jefferies Pan-European Mid-Cap Conference London
APR 30	2026	Quarterly Statement 1st Quarter 2026
MAY 5	2026	Annual General Meeting 2026
MAY 21	2026	Berenberg European Conference Manhattan
JUL 30	2026	Half-year Financial Report 2026
SEP 8	2026	Berenberg Food Ingredients & Chemicals Conference London
OCT 29	2026	Quarterly Statement 3rd Quarter 2026

*subject to change

ALL DATES AT A
GLANCE

 [Financial calendar](#)



FEEDBACK

We appreciate your feedback



Were your expectations met?
Are you missing any content?

WE APPRECIATE YOUR FEEDBACK!

[Link](#)

QR-Code



**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q4 2025

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

KPI IMPACT OF CUSTOMER GRANTS

Timing and effects on balance sheet and P&L



KPI EFFECTS

2025/2026


Cash / Assets	↑
Other receivables	↑
Equity	→
Contract liabilities	↑
Equity ratio	↓
Sales	→
EBITDA	→

KPI EFFECTS

2027 et seq.

Cash / Assets	→
Other receivables	↓
Equity	↑
Contract liabilities	↓
Equity ratio	↑
Sales	↑
EBITDA	↑


EST KEY EFFECTS ¹



ACTUAL 1-12/2025 EFFECTS in M€



EST CASH ²



1) Only customer investment contribution / 2) Based on our current best estimate and ongoing negotiations

BALANCE SHEET

Alzchem Group



ALZCHEM GROUP (IN T€)

	31.12.2024	31.12.2025	Deviation	
Intangible assets	3,671	3,530	-141	-3.8%
Tangible assets	192,976	276,980	84,005	43.5%
Investment properties				
Right of use (assets)	4,023	2,992	-1,031	-25.6%
Investments accounted for using the equity method				
Financials assets	6	6		
Trade receivables				
Other receivables	1,235	21,801	20,566	>1.000%
<i>there of Deferred tax assets for pensions provisions</i>				
Deferred tax assets	20,121	15,711	-4,410	-21.9%
SUM NON-CURRENT ASSETS	222,031	321,019	98,988	44.6%
Inventories	101,166	116,004	14,838	14.7%
Trade receivables	78,935	73,416	-5,519	-7.0%
Financial assets		0	0	
Other receivables	20,080	35,201	15,121	75.3%
Income tax receivables	71	319	248	350.7%
Cash and cash equivalents	61,544	71,720	10,176	16.5%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	261,795	296,660	34,865	13.3%
SUM ASSETS	483,826	617,679	133,852	27.7%

ALZCHEM GROUP (IN T€)

	31.12.2024	31.12.2025	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	186,843	232,111	45,269	24.2%
Other comprehensive income	-18,080	-12,398	5,681	-31.4%
Own shares	-1,512	-4,111	-2,600	172.0%
SHARE TO THE SHAREHOLDERS	205,536	256,296	50,760	24.7%
Non-controlling interests	1,934	1,934		
SUM EQUITY	207,471	258,231	50,760	24.5%
Provisions for pensions	96,937	88,239	-8,698	-9.0%
Other provisions	22,209	18,981	-3,228	-14.5%
Loans	41,082	34,750	-6,333	-15.4%
Finance lease liabilities	2,326	1,239	-1,088	-46.7%
Trade liabilities		14	14	
Contract liabilities		88,099	88,099	
Other liabilities	647	492	-155	-24.0%
Deferred tax liabilities	7,755	8,730	975	12.6%
SUM NON-CURRENT LIABILITIES	170,956	240,543	69,587	40.7%
Other provisions	3,413	7,190	3,777	110.7%
Loans	7,589	6,368	-1,220	-16.1%
Finance lease liabilities	1,826	1,874	48	2.6%
Finance liabilities	1,994		-1,994	-100.0%
Trade liabilities	37,425	51,726	14,301	38.2%
Contract liabilities		2,433	2,433	
Other liabilities	39,974	38,340	-1,635	-4.1%
Income tax liabilities	13,178	10,973	-2,205	-16.7%
SUM CURRENT LIABILITIES	105,399	118,904	13,505	12.8%
Sum EQUITY AND LIABILITIES	483,826	617,679	133,852	27.7%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Interest rates increased from 3.4% to 4.1%
- Pension payments develop as expected with 2.6M€ - pension obligation has a long maturity with approx. 30 years payout period

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Deviation (Q4)	
Revenue	150,064	136,191	128,937	139,040	144,680	142,879	137,266	137,290	-1,749	-1%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	-6,521	12,682	-4,310	-7,169	11,436	3,433	624	545	7,714	-108%
Other income	3,558	3,731	3,716	6,295	5,263	5,006	3,806	9,266	2,971	47%
Raw materials and consumables used	-53,237	-57,999	-40,548	-43,880	-64,236	-47,293	-43,769	-42,989	891	-2%
Employee benefits expense	-40,589	-42,468	-38,100	-39,343	-41,150	-44,894	-43,245	-44,322	-4,979	13%
Other expense	-28,367	-25,118	-24,813	-26,488	-28,632	-30,036	-24,957	-29,494	-3,006	11%
EBITDA	24,910	27,021	24,883	28,455	27,362	29,096	29,724	30,296	1,842	6%
Depreciation expense	-6,534	-6,453	-6,402	-6,928	-6,552	-6,435	-6,655	-7,007	-79	1%
Impairment										
EBIT	18,375	20,567	18,480	21,527	20,810	22,662	23,069	23,290	1,763	8%
Investment income										
Other interest and similar income	292	687	450	801	712	626	819	1,082	281	35%
Other interest and similar expense	-1,454	-1,366	-1,537	-1,480	-1,278	-1,284	-1,254	-1,314	165	-11%
Financial result	-1,162	-679	-1,087	-679	-567	-658	-436	-232	447	-66%
Result from associates										
Result from ordinary business	17,213	19,888	17,393	20,848	20,243	22,003	22,634	23,057	2,209	11%
Taxes on income and profit	-4,977	-5,460	-4,974	-5,685	-5,607	-6,128	-6,297	-6,276	-590	10%
<i>thereof income tax</i>	-4,463	-5,036	-4,473	-6,148	-4,537	-6,330	-5,550	-6,040	108	-2%
<i>thereof change from deferred taxes</i>	-514	-424	-501	463	-1,070	202	-748	-235	-698	-151%
Annual result	12,237	14,428	12,419	15,163	14,636	15,876	16,337	16,782	1,619	11%
<i>thereof minority interests</i>	43	43	43	43	43	43	43	43		
<i>thereof shares held by shareholders</i>	12,194	14,385	12,376	15,120	14,594	15,833	16,294	16,739	1,619	11%
Result per share in EUR	1.20 €	1.41 €	1.22 €	1.49 €	1.44 €	1.57 €	1.61 €	1.66 €		

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

	Q4 2024	Q4 2025	Deviation (QoQ)		YTD Dez.2024	YTD Dez.2025	Deviation (YoY)	
Revenue	139,040	137,290	-1,749	-1.3%	554,231	562,115	7,884	1.4%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	-7,169	545	7,714	-107.6%	-5,317	16,038	21,355	-401.6%
Other income	6,295	9,266	2,971	47.2%	17,301	23,342	6,041	34.9%
Raw materials and consumables used	-43,880	-42,989	891	-2.0%	-195,663	-198,286	-2,622	1.3%
Employee benefits expense	-39,343	-44,322	-4,979	12.7%	-160,499	-173,611	-13,112	8.2%
Other expense	-26,488	-29,494	-3,006	11.3%	-104,786	-113,119	-8,333	8.0%
EBITDA	28,455	30,296	1,842	6.5%	105,268	116,479	11,212	10.7%
Depreciation expense	-6,928	-7,007	-79	1.1%	-26,318	-26,649	-331	1.3%
Impairment	0	0	0		0	0	0	
EBIT	21,527	23,290	1,763	8.2%	78,950	89,831	10,881	13.8%
Investment income	0	0	0		0	0	0	
Other interest and similar income	801	1,082	281	35.1%	2,230	3,238	1,008	45.2%
Other interest and similar expense	-1,480	-1,314	165	-11.2%	-5,837	-5,131	706	-12.1%
Financial result	-679	-232	447	-65.8%	-3,607	-1,893	1,714	-47.5%
Result from associates	0	0	0		0	0	0	
Result from ordinary business	20,848	23,057	2,209	10.6%	75,343	87,938	12,595	16.7%
Taxes on income and profit	-5,685	-6,276	-590	10.4%	-21,097	-24,307	-3,211	15.2%
<i>thereof income tax</i>	-6,148	-6,040	108	-1.8%	-20,120	-22,457	-2,337	11.6%
<i>thereof change from deferred taxes</i>	463	-235	-698	-150.8%	-977	-1,851	-874	89.5%
Annual result	15,163	16,782	1,619	10.7%	54,246	63,630	9,384	17.3%
<i>thereof minority interests</i>	43	43	0	0.0%	171	171	0	0.0%
<i>thereof shares held by shareholders</i>	15,120	16,739	1,619	10.7%	54,075	63,459	9,384	17.4%
Result per share in EUR	1.49 €	1.66 €	0	11.4%	5.31 €	6.28 €	1	18.3%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

	Q4 2024	Q4 2025	1 - 12 2024	1 - 12 2025
Consolidated earnings before taxes	20.848	23.057	75.343	87.938
Depreciation on fixed and intangible assets	6.928	7.007	26.318	26.649
Decrease in pension provisions	-614	-628	-2.265	-2.614
Loss (+) / Profit (-) from the sale of non-current assets	-4	0	30	21
Other non-cash income (-) and expenses (+)	11.635	5.621	20.941	8.781
Financial result	679	232	3.607	1.893
Interests & Taxes	-4.059	-4.514	-12.710	-16.956
Increase (+) / Decrease (-) Net Working Capital	-5.350	-12.486	-6.117	-27.463
Payments from customer grants		3.227		58.765
Cashflow from ongoing operations (Net cash flow)	30.063	21.516	105.147	137.013
Cash outflows for investments in fixed assets	-16.770	-30.318	-43.101	-97.789
Cash inflows from the sale of fixed assets	93	0	60	40
Cash inflows from grants received for investments	12.046	846	12.046	846
Cashflow from investing activity	-4.630	-29.472	-30.994	-96.902
Free cashflow	25.432	-7.956	74.153	40.111
Deposits (+) / Repayment (-) bank loans long-term				
Repayment of bank loans long-term	-2.646	-1.583	-8.833	-7.583
Deposits (+) / Repayment (-) from short-term financing lines				
Dividend payments			-12.212	-18.190
Payment of reduction in leasing liabilities	-596	-478	-1.928	-1.915
Payments for the acquisition of own shares (incl. transaction costs)	-1.512	-914	-1.512	-4.520
Payments for the issue of own shares		3.019		3.019
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	-4.754	44	-24.655	-29.360

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES

SALES	2023				2024				2025				Deviation PY (Q4)		YTD Q4 2025		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%	PY T€	Actual T€	T€	%
Basics & Intermediates	57,337	46,038	44,271	44,538	49,299	41,848	40,927	41,929	42,638	35,605	43,309	33,539	-8,390	-20%	174,003	155,091	-18,911	-11%
Specialty Chemicals	85,783	73,172	69,545	91,302	92,961	85,805	80,354	88,969	94,512	100,128	86,978	97,159	8,190	9%	348,089	378,776	30,687	9%
Other and Holding	7,312	7,389	7,007	6,955	7,804	8,538	7,656	8,142	7,530	7,146	6,979	6,592	-1,549	-19%	32,140	28,247	-3,892	-12%
<i>Group Consolidation</i>																		
Alzchem Group	150,432	126,599	120,824	142,794	150,064	136,191	128,937	139,040	144,680	142,879	137,266	137,290	-1,749	-1%	554,231	562,115	7,884	1%

EBITDA

EBITDA	2023				2024				2025				Deviation PY (Q4)		YTD Q4 2025		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%	PY T€	Actual T€	T€	%
Basics & Intermediates	2,780	2,410	1,065	3,275	1,802	3,055	1,827	4,142	140	1,174	3,754	549	-3,593	-87%	10,825	5,617	-5,208	-48%
Specialty Chemicals	16,019	14,936	18,541	23,747	22,684	22,843	21,749	26,741	26,041	27,854	24,117	28,782	2,041	8%	94,017	106,794	12,777	14%
Other and Holding	475	438	721	-1,171	537	849	1,114	-711	307	50	596	-287	424	60%	1,789	667	-1,122	-63%
<i>Group Consolidation</i>	-357	88	-793	-802	-113	274	194	-1,717	874	18	1,257	1,253	2,970	173%	-1,362	3,402	4,764	-350%
Alzchem Group	18,917	17,872	19,534	25,049	24,910	27,021	24,883	28,455	27,362	29,096	29,724	30,296	1,842	6%	105,268	116,479	11,211	11%

ALZCHEM GROUP LOCATIONS

Production sites and sales companies



- SALES COMPANY
- PRODUCTION SITE


Production facilities in Germany (4) and Sweden (1) and HQ in Trostberg (GER)

"VERBUND" – FULLY INTEGRATED BUSINESS MODEL

Vertically integrated production of chemical products based on the NCN chain



- Segment Specialty Chemicals
- Segment Basics & Intermediates



BENEFITS OF "VERBUND"

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

GLOBAL DEVELOPMENTS AS GROWTH DRIVERS



POPULATION GROWTH



LONGER LIFE EXPECTANCY



CLIMATE CHANGE



SUSTAINABILITY



SAFETY & DEFENCE

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A nutritional additive for poultry and pigs	Feed additive
	Creapure®	Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Creavitalis®	Creatine for health and food applications	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
Nitroguanidine	Intermediates for explosives and agrochemical products	Agriculture, Automotive, Defense	

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags. key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	NITRALZ[®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Eminex [®]	Reduction of methane emissions during storage of manure	Agriculture
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	<p>Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, Master Builders Solution, Sika, Firmenich, Klüh Catering, VIACTIV)</p> <p>Site services</p> <p>Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments</p>		


KEY SHARE DATA

Share details as of February 25, 2026



SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE	EUR 161.20
MARKET CAPITALIZATION	EUR 1,640.43 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
STOCK MARKET SEGMENT	SDAX since October 2, 2024
DESIGNATED SPONSOR	LBBW ODDO BHF SE

SHAREHOLDER STRUCTURE



As of January 2026. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the "Guide to the DAX Equity Indices."